Exscientia



‘4318 (PKC-theta)
(in-licensed by BMY)
Positive early Phase 1 results

Forward-looking Statements

This presentation and accompanying oral presentation (referred to herein collectively as the "presentation") contain express and implied forward-looking statements that involve substantial risks and uncertainties. All statements contained in this presentation, other than statements of historical facts, including statements regarding expectations of Exscientia plc ("we," "us", "our," or "Exscientia"), our strategy, future operations, future financial position, projected costs, prospects, plans, potential market and growth opportunities, competitive position, market trends, addressable market opportunity and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "target," "potential," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

Forward-looking statements speak only as of the date of this presentation, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events, except as required by applicable law. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the Securities and Exchange Commission ("SEC") after the date of this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

This presentation contains estimates, projections and other information concerning our industry, our business and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are responsible for the accuracy of such information and believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.

PKC-theta: Positive early results from Phase 1 study

Expert led AI designed compound in-licensed by BMY, in August 2021

Potential First-in-class Immunology Asset

- High-value immunology target that had **eluded many large biopharmas** due to selectivity challenges
- **Balanced profile** provided improvements in human whole blood potency and predicted human dose <200 mg/day
- **Excellent selectivity** versus near neighbours and broad kinome
- Positive early results from Ph1 study announced in May 2024

Key Elements of TPP

- 24 hrs coverage of IC_{80} required to drive efficacy
- Predicted human dose <200 mg/day
- High demands on target potency, selectivity, pharmacokinetics
- Robust translation into cellular and human whole blood assays

Better Efficacy at Approximately Half the Dose



Large pharma failures on an attractive target

Potential first-in-class immunology target



Our approach

Fragments. 2D and 3D generative design. Hotspots and multi-task models

Experiment

- Diverse ligand data sources. Proprietary fragment and kinase focussed **SPR screens** provided additional **seed data**
- Established and routinely executed key human whole blood assay

Expert-led AI Solutions

- **Generative design** rapidly explored selectivity-focussed scaffolds; **MERIT** analysis quantified the most promising
- **Hotspot** and **multi-task models** drove local and global kinase selectivity, respectively

Best-in-class Compound

- Nominated candidate designed in **<11 months** and was **150th novel compound** prepared
- Demonstrates close relationship at Exscientia of AI and experiment
- Elegant solution to a challenging problem; Nominated candidate <400 MW

Exscientia

Exscientia plc

OXFORD HEADQUARTERS
The Schrödinger Building
Oxford Science Park
Oxford OX4 4GE

investors@exscientia.ai



Registered address: The Schrödinger Building,
Oxford Science Park, Oxford, OX4 4GE, United Kingdom

Registered number: 13483814